NewEdge Advisors LLC Purchases 2,626 Shares of IQVIA Holdings Inc. $IQV

Key Points

• NewEdge Advisors LLC increased its stake in IQVIA Holdings Inc. by 13.9% during the first quarter, purchasing an additional 2,626 shares, bringing its total to 21,576 shares valued at approximately $3.8 million.
• Multiple institutional investors have significantly modified their positions in IQVIA, with American National Bank & Trust and Clal Insurance Enterprises Holdings Ltd among those making new investments or increasing their holdings.
• Analysts have raised their price targets for IQVIA, with price estimates ranging from $180 to $235, indicating a consensus "Moderate Buy" rating among 18 analysts.

NewEdge Advisors LLC raised its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 13.9% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 21,576 shares of the medical research company's stock after buying an additional 2,626 shares during the quarter. NewEdge Advisors LLC's holdings in IQVIA were worth $3,804,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Sowell Financial Services LLC acquired a new position in IQVIA in the first quarter valued at approximately $305,000. Mather Group LLC. lifted its stake in IQVIA by 83.5% in the first quarter. Mather Group LLC. now owns 769 shares of the medical research company's stock valued at $136,000 after buying an additional 350 shares during the period. Private Advisor Group LLC lifted its stake in IQVIA by 11.6% in the first quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company's stock valued at $958,000 after buying an additional 566 shares during the period. Park Avenue Securities LLC lifted its stake in IQVIA by 40.4% in the first quarter. Park Avenue Securities LLC now owns 5,425 shares of the medical research company's stock valued at $956,000 after buying an additional 1,562 shares during the period. Finally, Wealth Enhancement Advisory Services LLC raised its position in shares of IQVIA by 34.5% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 13,259 shares of the medical research company's stock worth $2,338,000 after purchasing an additional 3,398 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Performance

NYSE:IQV traded down $3.35 during trading on Friday, reaching $187.34. The company's stock had a trading volume of 946,284 shares, compared to its average volume of 1,144,220. The firm has a market cap of $31.85 billion, a price-to-earnings ratio of 27.11, a price-to-earnings-growth ratio of 2.09 and a beta of 1.32. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. The firm has a 50 day moving average of $182.40 and a 200-day moving average of $167.42. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $248.03.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. The firm had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business's revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Truist Financial upped their target price on IQVIA from $209.00 to $235.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. Jefferies Financial Group raised IQVIA from a "hold" rating to a "buy" rating and upped their target price for the stock from $195.00 to $225.00 in a research report on Tuesday. Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a research report on Thursday, May 22nd. Mizuho upped their target price on IQVIA from $190.00 to $225.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Finally, William Blair reaffirmed an "outperform" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Eighteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $229.64.

Insiders Place Their Bets

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares in the company, valued at $557,352.30. This represents a 15.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the company's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the transaction, the insider owned 27,178 shares of the company's stock, valued at $5,165,178.90. This trade represents a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.